The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
The product will be marketed by Dr. Reddy's
He did Master’s of Pharmacy (Pharmaceutical Technology, Formulations) from National Institute of Pharmaceutical Education and Research, Mohali and Bachelor of Pharmacy from Osmania University
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The proceeds from its fresh issuance to the extent of Rs 107 crore will be utilized for funding the capital expenditure requirements
Granules now has a total of 67 ANDA approvals from the USFDA
Stable profits, low leverage to keep credit profiles comfortable
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim
Subscribe To Our Newsletter & Stay Updated
